Filter results

Normal Renal Function clinical trials

View clinical trials related to Normal Renal Function.

Filter by:

None
Page 1

NCT ID: NCT04699877 Completed - Clinical trials for Normal Renal Function

A Study to Investigate the Effect of Severe Renal Impairment on Gilteritinib Compared to Healthy Participants With Normal Renal Function

Start date: January 28, 2021
Phase: Phase 1
Study type: Interventional

The purpose of the study was to evaluate the pharmacokinetics of a single oral dose of gilteritinib in male and female participants with severe renal impairment compared to healthy male and female participants with normal renal function. This study also evaluated safety and tolerability of a single oral dose of gilteritinib in male and female participants with severe renal impairment and healthy male and female participants with normal renal function. Part 2 of the study (mild and moderate renal impairment) was not conducted based on the final pharmacokinetic findings from part 1 (severe renal impairment).

NCT ID: NCT04656795 Completed - Renal Impairment Clinical Trials

PK Study in Subjects With Renal Impairment (Severe and if Required Mild & Moderate) Compared to Subjects With Normal Renal Function

Start date: December 2, 2020
Phase: Phase 1
Study type: Interventional

This is an open-label, non randomised, single-dose, study in male and female subjects with renal impairment (severe and if required mild & moderate) compared to male and female subjects with normal renal function.

NCT ID: NCT02965040 Completed - Clinical trials for Impaired Renal Function

A Phase 1 Study of Roxadustat in Subjects With Different Degrees of Renal Function

Start date: December 12, 2016
Phase: Phase 1
Study type: Interventional

For subjects with normal renal function or severely impaired renal function, this study will evaluate the pharmacokinetics of roxadustat and its main metabolites in plasma and urine. For subjects with end stage renal disease (ESRD) on continuous ambulatory peritoneal dialysis (CAPD) or automated peritoneal dialysis (APD), this study will evaluate the pharmacokinetics of roxadustat and its main metabolites in plasma, urine and dialysate. For subjects with ESRD on hemodialysis (HD) or hemodiafiltration (HDF), this study will evaluate the pharmacokinetics of roxadustat and its main metabolites in plasma, urine and dialysate and also the effect of dialysis on the pharmacokinetics of roxadustat and its main metabolites.

NCT ID: NCT02431481 Completed - Clinical trials for Impaired Renal Function

Evaluation of Renal Function Impairment on the Pharmacokinetics of LEE011

Start date: October 23, 2015
Phase: Phase 1
Study type: Interventional

The purpose of this study is to characterize the PK and safety profile of LEE011 following a single oral dose in adult subjects with various degrees of renal impairment compared to a matched group of healthy subjects with normal renal function.

NCT ID: NCT00543075 Completed - Clinical trials for Normal Renal Function

Pharmacokinetic Study of Genasense in Subjects With Normal Renal Function, Mildly Impaired Renal Function, and Moderately Impaired Renal Function

Start date: May 2006
Phase: Phase 1
Study type: Interventional

To characterize the pharmacokinetics of G3139 in subjects with normal, mildly impaired, and moderately impaired renal function who receive Genasense 3 mg/kg/day by continuous intravenous infusion for 2 days (48 hours).